Taro's Brampton facility regains FDA acceptable regulatory status

Apr 25 2011

Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company", Pink Sheets: TAROF) today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that after a February 2011 re-inspection of its Canadian manufacturing facility, the site has an acceptable regulatory status. Therefore, the issues noted in the February 5, 2009 warning letter are considered to be resolved.

"We have worked diligently at the Brampton facility to resolve the issues noted in the last inspection and are pleased that our efforts have brought the facility back into good standing with the Agency. We are dedicated to developing and manufacturing quality products for our customers while meeting and exceeding all Good Manufacturing Practices (GMP) standards set by the FDA and Health Canada," said James Kedrowski, Interim Chief Executive Officer of Taro.